Table 1. Percentages of ovarian cancer tumours expressing CRH, CRHR1, CRHR2 or FasL peptides, sorted by tumour stage.
| Peptide(s) | Tumour stage | Positive cases | Negative cases |
|---|---|---|---|
| CRH | II | 40% (4/10) | 60% (6/10) |
| III | 72% (18/25) | 28% (7/25) | |
| IV | 83.3% (10/12)a | 16.7% (2/12) | |
| CRHR1 | II | 60% (6/10) | 40% (4/10) |
| III | 72% (18/25) | 28% (7/25) | |
| IV | 75% (9/12) | 25% (3/12) | |
| CRHR2 | II | 50% (5/10) | 50% (5/10) |
| III | 68% (17/25) | 32% (8/25) | |
| IV | 66.7% (8/12) | 33.3% (4/12) | |
| FasL | II | 40% (4/10) | 60% (6/10) |
| III | 64% (16/25) | 36% (9/25) | |
| IV | 83.3% (10/12)a | 16.7% (2/12) | |
| CRH/CRHR1/FasL | II | 30% (3/10) | 70% (7/10) |
| III | 48% (12/25) | 52% (13/25) | |
| IV | 66.7% (8/12) | 33.3% (4/12) |
a
Percentage of stage IV tumours expressing CRH or FasL was significantly higher than that of stage II tumours (P<0.05).